Who are The ticagrelor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rivaroxaban and ticagrel therapy, Patent clopidogrel, low-dose ticagrelor, CYP2C19 genotype guided P2Y12 monotherapy, Clopidogrel loading, Integral ticagrelor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/the-ticagrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

The ticagrelor — Competitive Intelligence Brief

The ticagrelor (The ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor inhibitor. Area: Cardiovascular.

phase 3 P2Y12 receptor inhibitor P2Y12 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

The ticagrelor (The ticagrelor) — Sichuan Provincial People's Hospital. Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
The ticagrelor TARGET	The ticagrelor	Sichuan Provincial People's Hospital	phase 3	P2Y12 receptor inhibitor	P2Y12
rivaroxaban and ticagrel therapy	rivaroxaban and ticagrel therapy	Beijing Anzhen Hospital	marketed	Anticoagulant and antiplatelet combination therapy	Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor)
Patent clopidogrel	Patent clopidogrel	Hospital Central San Luis Potosi, Mexico	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
low-dose ticagrelor	low-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	marketed	P2Y12 receptor antagonist	P2Y12
CYP2C19 genotype guided P2Y12 monotherapy	CYP2C19 genotype guided P2Y12 monotherapy	St. Antonius Hospital	marketed	P2Y12 inhibitor (antiplatelet agent)	P2Y12 receptor
Clopidogrel loading	Clopidogrel loading	Azienda Policlinico Umberto I	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Integral ticagrelor	Integral ticagrelor	Collegium Medicum w Bydgoszczy	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor inhibitor class)

Sichuan Provincial People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/the-ticagrelor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab